{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05210582",
            "orgStudyIdInfo": {
                "id": "CUV104"
            },
            "organization": {
                "fullName": "Clinuvel Pharmaceuticals Limited",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Assess the Changes in Pigmentation and Safety of Afamelanotide in Patients With Vitiligo on the Face",
            "officialTitle": "An Open Label, Phase II Study to Assess the Changes in Pigmentation and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants in the Treatment of Vitiligo on the Face",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-study-to-assess-the-changes-in-pigmentation-and-safety-of-afamelanotide-in-patients-with-vitiligo-on-the-face"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-10-11",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2023-04",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2023-08",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-01-11",
            "studyFirstSubmitQcDate": "2022-01-11",
            "studyFirstPostDateStruct": {
                "date": "2022-01-27",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-02-07",
            "lastUpdatePostDateStruct": {
                "date": "2023-02-09",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Clinuvel, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The CUV104 study will assess the efficacy and safety of afamelanotide in patients with vitiligo on the face and body as a monotherapy in repigmentation."
        },
        "conditionsModule": {
            "conditions": [
                "Vitiligo"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 6,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Afamelanotide",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Afamelanotide"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Afamelanotide",
                    "description": "Patients will receive afamelanotide over a three-month period, with an additional three-month follow up.",
                    "armGroupLabels": [
                        "Afamelanotide"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Proportion of participants achieving Vitiligo Area Scoring Index (VASI)25 on facial lesions",
                    "description": "Measured using Vitiligo Area Scoring Index (VASI). A decrease in VASI indicates a reduction of the facial surface area affected by vitiligo (possible range 1-100)",
                    "timeFrame": "From Baseline to Day 84"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Proportion of participants achieving Vitiligo Area Scoring Index (VASI)25 on body surface area",
                    "description": "Proportion of participants achieving VASI25 on body surface area (excluding hands and feet). A decrease in VASI indicates a reduction of the facial surface area affected by vitiligo (possible range 1-100).",
                    "timeFrame": "From Baseline to Day 84"
                },
                {
                    "measure": "Percentage change in pigmentation on body surface area measured by the VASI scoring system",
                    "description": "Percentage change in pigmentation on body surface area (excluding hands and feet) measured by VASI scoring system. A decrease in VASI indicates a reduction of the body surface area affected by vitiligo (possible range 1-100)",
                    "timeFrame": "From Baseline to Day 84"
                },
                {
                    "measure": "Percentage change in pigmentation on facial surface area measured by the VASI scoring system",
                    "description": "A decreased VASI indicates a reduction in the faces' degree of depigmentation (possible range 1-100)",
                    "timeFrame": "From Baseline to Day 168"
                },
                {
                    "measure": "Change in Perception of Vitiligo Severity using a vitiligo validated specific tool (A)",
                    "description": "The higher the score, the more severe the disease",
                    "timeFrame": "From Baseline to Day 168"
                },
                {
                    "measure": "Change in Noticeability of Vitiligo using a vitiligo validated specific tool (B)",
                    "description": "Higher the value means lower noticeability",
                    "timeFrame": "From Baseline to Day 168"
                },
                {
                    "measure": "Change in Quality of life using a vitiligo specific tool (C)",
                    "description": "Higher value means a lower quality of life",
                    "timeFrame": "From Baseline to Day 168"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Male and female patients with a confirmed diagnosis of vitiligo on the face and with T-VASI range 0.5-50%\n* Stable face vitiligo with F-VASI of at least 0.1%\n* Stable or slowly progressive vitiligo over a 3-month period\n* Fitzpatrick skin types IV-VI\n* Treatment with narrowband (NB)-UVB light 2-3 times per week during the last four weeks preceding the first implant for priming\n\nExclusion Criteria:\n\n* Patients with segmental vitiligo\n* Fitzpatrick skin types I-III\n* Treatment with NB-UVB phototherapy in the last three months prior to phototherapy, excluding the sessions for priming in the four weeks prior to treatment. A 3-month washout period from phototherapy is necessary prior to priming.\n* Previous topical treatment for vitiligo\n* Allergy to afamelanotide or the polymer contained in the implant or to lignocaine/lidocaine or other local anaesthetic to be used during the administration of the implant\n* History of melanoma or lentigo maligna\n* Any current skin disease that may interfere with the study evaluation\n* Presence of severe hepatic disease or hepatic impairment\n* Renal impairment\n* History of systemic or psychiatric disease judged to be clinically significant by the Investigator and which may interfere with the study evaluation\n* Female who is pregnant or lactating\n* Female of child-bearing potential not using adequate contraceptive measures during the treatment phase and for a period of three months thereafter\n* Sexually active man with a partner of child-bearing potential who is not using adequate contraceptive measures, as described above\n* Participation in a clinical trial for an investigational agent within 30 days prior to the Screening Visit\n* Use of any other prior and concomitant therapy which may interfere with the objective of the study\n* Subjects assessed as not suitable for the study in the opinion of the Investigator",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "75 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Head of Clinical Operations",
                    "role": "CONTACT",
                    "phone": "+441372860765",
                    "email": "mail@clinuvel.com"
                }
            ],
            "locations": [
                {
                    "facility": "CLINUVEL Investigational site",
                    "status": "RECRUITING",
                    "city": "Detroit",
                    "state": "Michigan",
                    "zip": "48202",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.33143,
                        "lon": -83.04575
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000014820",
                    "term": "Vitiligo"
                }
            ],
            "ancestors": [
                {
                    "id": "D000017496",
                    "term": "Hypopigmentation"
                },
                {
                    "id": "D000010859",
                    "term": "Pigmentation Disorders"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M21089",
                    "name": "Facies",
                    "relevance": "LOW"
                },
                {
                    "id": "M17563",
                    "name": "Vitiligo",
                    "asFound": "Vitiligo",
                    "relevance": "HIGH"
                },
                {
                    "id": "M19761",
                    "name": "Hypopigmentation",
                    "relevance": "LOW"
                },
                {
                    "id": "M13754",
                    "name": "Pigmentation Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T2945",
                    "name": "Hypomelanotic Disorder",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000534526",
                    "term": "Afamelanotide"
                }
            ],
            "ancestors": [
                {
                    "id": "D000003879",
                    "term": "Dermatologic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M287422",
                    "name": "Afamelanotide",
                    "asFound": "Adiponectin",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7074",
                    "name": "Dermatologic Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Derm",
                    "name": "Dermatologic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}